COMMUNIQUÉS West-GlobeNewswire

Rapid Nutrition Enhances Investor Access with Agentic AI driven On-Demand Communication Platform
06/05/2026
LONDON, May 05, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech company advancing wellness through evidence-based, personalized nutrition solutions, today announced the [...]
WriteUpp Introduces Embedded AI Medical Scribe With SOAP, DAP and BIRP Note Generation at CA$40 Per User
06/05/2026
The new per-user add-on brings structured AI clinical documentation into Notes, Documents, and Assessments, giving Canadian therapists, physiotherapists, and allied health professionals a flexible and compliant way to [...]
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
06/05/2026
NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has [...]
HealthEquity Announces First Quarter Earnings Release Date and Investor Conference Schedule
05/05/2026
DRAPER, Utah, May 05, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume and a leader in [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/05/2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that [...]
Ligand to Participate in May Investor Conferences
05/05/2026
JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. [...]
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
05/05/2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory [...]
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/05/2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of [...]
Carlsmed® Reports First Quarter 2026 Financial Results
05/05/2026
First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc [...]
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
05/05/2026
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Claseprubart granted Orphan Drug [...]
Hyperion DeFi Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
05/05/2026
DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today announced that it intends to [...]
Dentsply Sirona Reports First Quarter 2026 Results
05/05/2026
News Summary Reported net sales of $880 million Delivered GAAP gross margin of 48.5% , GAAP net loss per share of ($0.05) Achieved adjusted gross margin of 50.7% , adjusted EBITDA margin of 14.7% , adjusted EPS of $0.27 [...]
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
05/05/2026
Successfully met primary endpoint of HiSCR75 for both doses studied, demonstrating response rates of 42.2% for 150 mg dose (p=0.018) and 42.9% for 300 mg dose (p=0.015) at Week 16, which are the highest rates observed [...]
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
05/05/2026
First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R [...]
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
05/05/2026
U.S. Launch of MYQORZO ® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ and Maximal Exercise [...]
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
05/05/2026
Highl ights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test. First quarter 2026 test volume reflects 13% and 7 [...]
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
05/05/2026
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
05/05/2026
Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued pipeline [...]
Korro to Participate in Upcoming Investor Conferences
05/05/2026
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class [...]

Pages